Learning about Abrocitinib for treating moderate to severe atopic dermatitis in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the safety and effectiveness of Abrocitinib in adult patients suffering from moderate to severe atopic dermatitis in a real-world clinical setting. Participants, aged 18 and older, will take Abrocitinib daily while also using topical treatments for their condition. The study will last for 24 months, during which participants will visit the clinic approximately every 4 to 6 months to monitor their experiences and outcomes. The goal is to gather data that will help determine the medicine's safety and its impact on treating atopic dermatitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients older than 18 years of age at inclusion.
* Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval.
* Patients that have been informed of the study procedures and have signed the consent.

Exclusion Criteria:

* Patients for whom abrocitinib is contraindicated.
* Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.
* Patients not affiliated to the French social security system.
* Patients deprived of liberty, under guardianship, or unable to provide oral consent.
* Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).

Where it's running

• CHU Amiens-Picardie - Site Nord
  Amiens, Somme, France Recruiting
• CHU Besancon - Hopital Jean Minjoz
  Besançon, France Recruiting
• Polyclinique Reims Bezannes
  Bezannes, France Recruiting
• Chu Bordeaux Hopital Saint Andre
  Bordeaux, France Recruiting
• CHU Brest Hopital Morvan
  Brest, France Recruiting
• CHU de Caen
  Caen, France Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital mindfulness app for teens with eczema

  Teens with moderate to severe eczema try a digital mindfulness app to see if it helps control symptoms and improve quality of life.

  Recruiting at 2 sites Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT07746427

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Low-sodium diet and salt tablets to see if eczema improves

  This study tests whether a low-sodium diet can lessen eczema symptoms in adults with atopic dermatitis, using a cross-over design with sodium tablets and placebo to see if salt intake changes skin sodium and severity.

  Recruiting at 2 sites Phase 4 University of California, San Francisco · San Francisco, California and 1 other locations · NCT07447063

• Soquelitinib for adults with moderate to severe atopic dermatitis

  This 12-week test gives adults with moderate to severe atopic dermatitis daily soquelitinib or a placebo to see if their skin and itch improve and to track side effects.

  Recruiting Phase 2 Corvus Pharmaceuticals, Inc. · South San Francisco, California · NCT07441395

• GX-03 topical treatment for adults with moderate to severe eczema

  This study will test whether applying GX-03, a topical emollient, twice daily for 8 weeks reduces eczema severity and itch in adults with moderate to severe atopic dermatitis compared with a petrolatum-based vehicle.

  Recruiting Phase 2/3 Turn Therapeutics · Irving, Texas · NCT07355075

• Abrocitinib for eczema and patchy hair loss in people with Down syndrome

  This trial will test whether taking abrocitinib daily can help improve eczema or patchy hair loss in people with Down syndrome aged 12 and up.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07242638

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.